CAR T-cell treatment for hard-to-treat B-cell blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 3 and under 70 years old (for ALL), or 18 to under 70 (for NHL).
- You have B-cell leukemia/lymphoma that is CD19-positive, such as B-ALL, or a qualifying lymphoma type for NHL.
- Your disease has come back or did not respond to prior standard treatment.
- Your bone marrow has enough cancer cells (over 5% by look under microscope and/or over 1% by flow testing).
- You do not have certain heart problems or recent major heart events, and your heart pumping is fairly strong (LVEF at least 50%).
- You have no serious uncontrolled infection and can meet basic health/lab thresholds (including liver and kidney tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial tests a personalized CAR-T cell treatment that targets a marker called CD79b in people whose B-blood cancers have come back or not responded to prior treatment. It may help your immune system find and attack cancer cells, but it also requires you to meet safety and health criteria.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
This trial tests a locally made CAR T-cell therapy that targets CD19 on cancer cells. It is for children and young adults with certain B-cell cancers that have come back or not responded to other treatments.
Hear when a new Relapsed and Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.